ArticleOncology letters2017
Associations of tumor suppressor SPARCL1 with cancer progression and prognosis.
Article in Oncology letters, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 30 citations in OpenAlex.
- SPARC family proteins: matricellular modulators of cancer progression and therapeutic resistance.Cancer gene therapy · 2026Review
- SPARCL1 Enrichment at the Glioblastoma Invasive Front Is Consistent with Synaptogenic and Angiogenic Tumor Niches.International journal of molecular sciences · 2026Article
- Proteomic pathways mediating low socioeconomic status and cardiovascular events in older adults in CHS and ARIC.Atherosclerosis · 2026Article
- Association Study ofGenes · 2025Article
- Glioma-derived SPARCL1 promotes the formation of peritumoral neuron-glioma synapses.Journal of neuro-oncology · 2025Article
- Article
- Spatial proteomics of Onchocerca volvulus with pleomorphic neoplasms shows local and systemic dysregulation of protein expression.PLoS neglected tropical diseases · 2025Article
- Epigenetic Biomarkers as a New Diagnostic Tool in Bladder Cancer-From Early Detection to Prognosis.Journal of clinical medicine · 2024Review
- The oncogenic functions of SPARCL1 in bladder cancer.Journal of cellular and molecular medicine · 2024Article
- 3D geometry orchestrates the transcriptional landscape of metastatic neuroblastoma cells in a multicellularMaterials today. Bio · 2023Article
- Glioblastoma microenvironment contains multiple hormonal and non-hormonal growth-stimulating factors.Fluids and barriers of the CNS · 2022Article
- SPARCL1 Is a Novel Prognostic Biomarker and Correlates with Tumor Microenvironment in Colorectal Cancer.BioMed research international · 2022Article
- Immunological role and prognostic value of SPARCL1 in pan-cancer analysis.Pathology oncology research : POR · 2022Article
- Apobec1 complementation factor overexpression promotes hepatic steatosis, fibrosis, and hepatocellular cancer.The Journal of clinical investigation · 2021Article
- Exploring TCGA database for identification of potential prognostic genes in stomach adenocarcinoma.Cancer cell international · 2020Article
- Combinatorial perturbation analysis reveals divergent regulations of mesenchymal genes during epithelial-to-mesenchymal transition.NPJ systems biology and applications · 2019Article
- Laser Capture Microdissection and RNA-Seq Analysis: High Sensitivity Approaches to Explain Histopathological Heterogeneity in Human Glioblastoma FFPE Archived Tissues.Frontiers in oncology · 2019Article
- Secreted protein acidic and rich in cysteine-like 1 suppresses metastasis in gastric stromal tumors.BMC gastroenterology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
SPARC-like protein 1 (SPARCL1), a member of the family of secreted proteins which is acidic and rich in cysteine, is a potential tumor suppressor gene in most types of tumor. A systemic review and bioinformatics analysis was carried out to determine the associations between SPARCL1 and tumor progression and clinical factors. Downregulation of SPARCL1, thought to be regulated by epigenetic modifications including DNA methylation, serves important functions in tumor progression and development, with its regulatory functions on cell viability, migration, invasion, cell adhesion and drug resistance. Downregulation of SPARCL1 was markedly associated with a poor overall survival rate of patients with one of ≥7 solid tumors and predicted increased mortality in patients with one of ≥4 distinct tumor types. The present review indicated that SPARCL1 may be a therapeutic target for cancer treatment and a biomarker to determine prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.